31. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial. Issue 3 (24th March 2023) Authors: Weisel, Katja; Dimopoulos, Meletios A.; San-Miguel, Jesús; Paner, Agne; Engelhardt, Monika; Taylor, Fiona; Lord-Bessen, Jennifer; Yip, Christine; Greenwood, Mike; Tang, Jackson; Cavo, Michele Journal: HemaSphere Issue: Volume 7:Issue 3(2023) Page Start: e843 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
32. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. (September 2021) Authors: Ramasamy, Karthik; Gay, Francesca; Weisel, Katja; Zweegman, Sonja; Mateos, Maria Victoria; Richardson, Paul Journal: Blood reviews Issue: Volume 49(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
33. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. (28th February 2019) Authors: Costello, Caitlin; Davies, Faith E; Cook, Gordon; Vela-Ojeda, Jorge; Omel, Jim; Rifkin, Robert M; Berdeja, Jesus; Puig, Noemi; Usmani, Saad Z; Weisel, Katja; Zonder, Jeffrey A; Terpos, Evangelos; Spencer, Andrew; Leleu, Xavier; Boccadoro, Mario; Thompson, Michael A; Romanus, Dorothy; Stull, Dawn ... Journal: Future oncology Issue: Volume 15:Number 13(2019) Page Start: 1411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
34. Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study. Issue 22 (27th July 2021) Authors: Lonial, Sagar; Lee, Hans C.; Badros, Ashraf; Trudel, Suzanne; Nooka, Ajay K.; Chari, Ajai; Abdallah, Al‐Ola; Callander, Natalie; Sborov, Douglas; Suvannasankha, Attaya; Weisel, Katja; Voorhees, Peter M.; Womersley, Lynsey; Baron, January; Piontek, Trisha; Lewis, Eric; Opalinska, Joanna; Gupta, Ir... Journal: Cancer Issue: Volume 127:Issue 22(2021) Page Start: 4198 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
35. Maintenance and continuous therapy for multiple myeloma. Issue 8 (3rd August 2018) Authors: Richardson, Paul G.; Laubach, Jacob; Gandolfi, Sara; Facon, Thierry; Weisel, Katja; O'Gorman, Peter Journal: Expert review of anticancer therapy Issue: Volume 18:Issue 8(2018) Page Start: 751 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
36. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Issue 10 (24th August 2021) Authors: Rodriguez-Otero, Paula; Ayers, Dieter; Cope, Shannon; Davies, Faith E.; Delforge, Michel; Mojebi, Ali; Jansen, Jeroen P.; Weisel, Katja; Hege, Kristen; Dhanasiri, Sujith Journal: Leukemia & lymphoma Issue: Volume 62:Issue 10(2021) Page Start: 2482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
37. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. (3rd October 2022) Authors: Costa, Luciano J.; Hari, Parameswaran; Berdeja, Jesus G.; De Stefano, Valerio; Gay, Francesca; Hooper, Becky; Bartlett, Meaghan; Haltner, Anja; Rosta, Emily; Kumar, Shaji; Martin, Thomas; Mateos, Maria-Victoria; Moreau, Philippe; Usmani, Saad Z.; Olyslager, Yunsi; Schecter, Jordan M.; Roccia, Tit... Journal: Current medical research and opinion Issue: Volume 38:Number 10(2022) Page Start: 1759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
38. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial. Issue 5 (May 2020) Authors: Raab, Marc S; Engelhardt, Monika; Blank, Antje; Goldschmidt, Hartmut; Agis, Hermine; Blau, Igor W; Einsele, Hermann; Ferstl, Barbara; Schub, Natalie; Röllig, Christoph; Weisel, Katja; Winderlich, Mark; Griese, Janine; Härtle, Stefan; Weirather, Johannes; Jarutat, Tiantom; Peschel, Christian; Chat... Journal: Lancet Issue: Volume 7:Issue 5(2020) Page Start: e381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
39. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Issue 7 (July 2018) Authors: Moreau, Philippe; Mateos, Maria-Victoria; Berenson, James R; Weisel, Katja; Lazzaro, Antonio; Song, Kevin; Dimopoulos, Meletios A; Huang, Mei; Zahlten-Kumeli, Anita; Stewart, A Keith Journal: Lancet oncology Issue: Volume 19:Issue 7(2018) Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
40. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM‐003 trial for pomalidomide plus low‐dose dexamethasone. (18th November 2014) Authors: Morgan, Gareth; Palumbo, Antonio; Dhanasiri, Sujith; Lee, Dawn; Weisel, Katja; Facon, Thierry; Delforge, Michel; Oriol, Albert; Zaki, Mohamed; Yu, Xin; Sternas, Lars; Jacques, Christian; Akehurst, Ron; Offner, Fritz; Dimopoulos, Meletios A. Journal: British journal of haematology Issue: Volume 168:Number 6(2015:Mar.) Page Start: 820 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗